[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-malformation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-malformation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100591940","beacon-tip-sizing-catheter-and-slip-cath-beacon-tip-catheter-study-100591940",false,"NCT06986954","Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study","Inclusion Criteria:\n\n* A patient is deemed suitable for inclusion in this study if the patient undergoes a procedure using an applicable Beacon Tip Catheter.\n\nExclusion Criteria:\n\n* Patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data, or not willing to accept the use of an Informed Consent waiver or the data protection notice (if utilized).","ALL",{"count":17,"type":18},588,"ESTIMATED","OBSERVATIONAL","This prospective observational post-market clinical study will collect data in the United States to primarily support the re-launch of the re-designed Beacon Tip Sizing Catheter and Slip-Catheter Beacon Tip Catheter \\& Shuttle Select Slip-Catheter (Visceral and Cerbral) for a Conformité Européenne (CE) Mark application in the European Union (EU). Additionally, the data from this study may be used to support regulatory approval in other countries\u002Fregions.\n\nThe purpose of this clinical study is to evaluate the safety and performance of these catheters in accordance with the Intended Use through the end of index procedure, and through 30 days post procedure, (as applicable as data is available) to ensure an acceptable benefit:risk ratio.",[22,23,24,25,26,27],"Stenosis","Bleed Intracranial","Stroke","TIA","Vascular Malformation","Pseudoaneurysm",[29,30,31,32,33],"Catheter","Beacon","Diagnostic imaging","Device sizing","Beacon tip slip cath","RECRUITING","2025-07-15",{"date":37,"type":38},"2025-07-16","ACTUAL",{"date":40,"type":38},"2025-04-20",{"date":42,"type":18},"2026-07-31",{"name":44,"class":45},"Cook Research Incorporated","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100592502","diagnostic-imaging-of-vascular-malformations-using-msot-and-ulm-100592502","NCT06994260","Diagnostic Imaging of Vascular Malformations Using MSOT and ULM","Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) as Diagnostic Imaging for Lymphatic, Venous and Arteriovenous Malformations","Inclusion Criteria:\n\n* Confirmed vascular malformations (arteriovenous, venous, or lymphatic).\n* ≥18 years old and able to give their consent\n\nExclusion Criteria:\n\n* No imaging for diagnostic confirmation has been performed or is planned.\n* Lack of written consent\n* \\\u003C18 years old\n* Safety concerns of the study physician (a patient with physical, psychological, or psychiatric conditions that, in the opinion of the study physician, could compromise the patient's safety or the quality of the data, thereby making the patient an unsuitable candidate for the study).","18 Years",{"count":56,"type":18},15,"This clinical study evaluates the efficacy and accuracy of Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) for imaging and diagnosing vascular malformations (venous, arteriovenous, lymphatic). The study aims to enhance diagnostic precision and improve treatment planning through advanced non-invasive imaging techniques.",[26,59,60,61],"Arteriovenous Malformation","Lymphatic Malformation","Venous Malformations",[26,63,59,60,64,65],"Venous Malformation","MSOT","ULM","NOT_YET_RECRUITING","2025-06-20",{"date":69,"type":38},"2025-06-22",{"date":71,"type":18},"2025-08-01",{"date":73,"type":18},"2026-06-01",{"name":75,"class":76},"University Hospital Erlangen","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":19,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100536012","comprehensive-hht-outcomes-registry-of-the-united-states-chorus-100536012","NCT06259292","Comprehensive HHT Outcomes Registry of the United States (CHORUS)","CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States","CHORUS","Inclusion Criteria:\n\n* Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.\n* Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.\n\nExclusion Criteria:\n\n* Unable to provide informed consent or informed consent via a parent or legally authorized representative.",true,{"count":87,"type":18},10000,"10 Years","The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease.\n\nAnother important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study.\n\nParticipants will:\n\n* Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information.\n* Be asked study-related questions by phone or at a clinic visit.\n* Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year\u002Fs including new test results, treatment information, symptoms, and complications from HHT.",[91,92,93,94,95,96,26],"Hereditary Hemorrhagic Telangiectasia","Arteriovenous Malformations","Telangiectasia","Epistaxis","GastroIntestinal Bleeding","Cerebral Arteriovenous Malformations","2025-06-10",{"date":99,"type":38},"2025-06-13",{"date":101,"type":38},"2023-11-13",{"date":103,"type":18},"2033-11",{"name":105,"class":76},"Cure HHT",16,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100576670","phase-2-a-study-of-enalapril-in-treatment-of-venous-malformations-100576670","NCT06788314","A Study of Enalapril in Treatment of Venous Malformations","A Single Center, Single Arm, Phase 2, Pilot Study to Investigate the Efficacy of the ACE Inhibitor Enalapril in Participants Aged 18-70 Years of Age With Painful Venous Malformations.","EVA","Inclusion Criteria:\n\n1. Patients with venous malformations verified by clinical examination, ultrasound and anatomic MRI with contrast. The venous malformation should have well defined borders and the volume should be measurable on MRI. Diagnosis of venous malformation shall be object for consensus in a multidisciplinary team meeting.\n2. Patients must experience pain from the malformation. Pain is defined as local pain in the malformation, and the participant must have pain that according to the patient inhibits daily activity or pain during nighttime that interferes with sleep. The symptoms has to reduces quality of life. NRS inclusion criteria is greater or equal to 4.\n3. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent.\n4. Negative urine pregnancy test in females with childbearing potential. A woman is considered of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n5. Woman of childbearing potential (WOCBP) must use highly effective contraception measures while on study medicine and for up to 2 weeks past treatment:\n\n   * Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation.\n   * Progestogen-only hormonal contraception associated with inhibition of ovulation Intrauterine device (IUS) Intrauterine hormone-releasing system (IUS) Bilateral tubal occlusion Vasectomized partner Sexual abstinence (controlled with regular questioning by PI)\n6. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). They must also be capable of answer adequately questionnaires regarding quality of life. Since the questionnaire are validated in Norwegian and English they also should control one of this language.\n\nExclusion Criteria:\n\n1. Diffuse VM with no defined borders.\n2. Known diabetes because of the risk of hypoglycemia.\n3. Impaired liver function (INR \\> 1,5 or aminotransferases \\> 3 times upper limit of normal\n4. Use of mTOR-inhibitor, racekadotril, sacubitril\u002Fvalsartan, ramipril or vildagliptin is contraindicated because of an elevated risk of angioedema\n5. Use of angiotensin-II receptor antagonist or alsikiren (direct renin inhibitor) is contraindicated because of increased risk of hypotension, hyperkalemia, and impaired renal function.\n6. Impaired cardiac function and clinically significant cardiac disease including aorta- and mitral valve stenosis and hypertrophic cardiomyopathy.\n7. Lactose intolerance, total lactase deficiency or glucose-galactose malabsorption because Enalapril contains lactose.\n8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the ACE-inhibitor (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea \\> grade 2, malabsorption syndrome, or small bowel resection.)\n9. Hypersensitivity to the active substance or any of the excipients listed in section 6.1 of the SmPC of enalpril or to other ACE-inhibitors.\n10. Patient has other concurrent severe and\u002For uncontrolled medical condition that would, in the investigator's judgment, contraindicated participation in the clinical study.\n11. Known renal artery stenosis.\n12. Patients with a history of angioneurotic edema related to previous treatment with ACE-inhibitors and patients with Hereditary or ideopatic anigioneurotic edema.\n13. Contraindications for MRI (cardiac pacemaker or defibrillator, intracranial clips, cochlear implants or other metallic foreign bodies, claustrophobia.\n14. BMI\\> 30\n15. Impaired kidney function (eGFR\\\u003C 50)\n16. Pregnant or lactating woman\n17. Any condition that in the view of the investigator would suggest that the patient is unable to compley with the study protocol and procedures.","70 Years",{"count":117,"type":18},12,"INTERVENTIONAL",[120],"PHASE2","The goal of this clinical trial is to explore if enalapril can be used to treat painful venous malformations. The main question it aims to answer are:\n\n\\- Can enalapril reduce pain and volume of the malformation and increase quality of life in patients with painful venous malformations?\n\nParticipants will:\n\nReceive a dose of enalapril 5 mg once daily. If it doesn't have effect the dose of enalapril will be increased to 10 mg daily after 3 months.\n\nThe treatment duration will be 12 months, with an additional follow-up of 12 months.\n\nThe visit frequency will be after 1, 3, 6,9 and 12 months and then a follow up visit at 18 and 24 months.\n\nApproximately 15 participants will be screened to achieve minimum 10 enrolled participants.",[63,123,124,26],"Pain","Quality of Life","2025-03-27",{"date":127,"type":38},"2025-04-02",{"date":129,"type":38},"2025-02-01",{"date":131,"type":18},"2030-12-01",{"name":133,"class":76},"Oslo University Hospital"]